New Insights into the Diagnosis of Alzheimer's and Dementia Using PET Presented at SNMMI 2015
By MedImaging International staff writers Posted on 16 Jun 2015 |
New research into plaque types and deposition patterns in Alzheimer's disease (AD) and dementia has been presented at annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI; Baltimore, MD, USA) during June 6–10, 2015.
The researchers used the diagnostic imaging agent florbetaben F18 (FBB) in Positron Emission Tomography (PET) to provide detailed information about the quantification and distribution of beta-amyloid plaques in the brain. One analysis evaluated data to determine the ability of FBB PET scans to detect beta-amyloid deposits that were morphologically distinct. Another study assessed the influence of cerebellar plaques on FBB Standardized Uptake Value Ratios (SUVR), using cerebellar gray matter as reference.
Piramal Imaging (Matran, Switzerland) presented the analyses which could help researchers better optimize patient care and initiate appropriate therapy for AD and dementia. Research results showed the accuracy of beta-amyloid imaging using florbetaben F18.
Andrew Stephens, chief medical officer, Piramal Imaging, said, "Past studies have shown that PET imaging with FBB and subsequent histopathology analyses provide greater detail assessment of beta-amyloid plaques in the brain. These new datasets build on this research, demonstrating PET with FBB may also contribute to an improved understanding of the role of beta-amyloid plaques in the brain including which factors in the brain influence and contribute to signal assessment."
Related Links:
SNMMI
Piramal Imaging
The researchers used the diagnostic imaging agent florbetaben F18 (FBB) in Positron Emission Tomography (PET) to provide detailed information about the quantification and distribution of beta-amyloid plaques in the brain. One analysis evaluated data to determine the ability of FBB PET scans to detect beta-amyloid deposits that were morphologically distinct. Another study assessed the influence of cerebellar plaques on FBB Standardized Uptake Value Ratios (SUVR), using cerebellar gray matter as reference.
Piramal Imaging (Matran, Switzerland) presented the analyses which could help researchers better optimize patient care and initiate appropriate therapy for AD and dementia. Research results showed the accuracy of beta-amyloid imaging using florbetaben F18.
Andrew Stephens, chief medical officer, Piramal Imaging, said, "Past studies have shown that PET imaging with FBB and subsequent histopathology analyses provide greater detail assessment of beta-amyloid plaques in the brain. These new datasets build on this research, demonstrating PET with FBB may also contribute to an improved understanding of the role of beta-amyloid plaques in the brain including which factors in the brain influence and contribute to signal assessment."
Related Links:
SNMMI
Piramal Imaging
Latest Nuclear Medicine News
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure